Hologic (HOLX) Scheduled to Post Quarterly Earnings on Wednesday

Hologic (NASDAQ:HOLXGet Rating) is set to post its quarterly earnings results after the market closes on Wednesday, February 1st. Analysts expect Hologic to post earnings of $0.90 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Hologic (NASDAQ:HOLXGet Rating) last released its quarterly earnings data on Monday, October 31st. The medical equipment provider reported $0.82 EPS for the quarter, topping the consensus estimate of $0.62 by $0.20. Hologic had a return on equity of 31.85% and a net margin of 26.77%. The company had revenue of $953.30 million for the quarter, compared to the consensus estimate of $861.68 million. During the same period last year, the business posted $1.61 EPS. Hologic’s quarterly revenue was down 27.6% on a year-over-year basis. On average, analysts expect Hologic to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Hologic Price Performance

Shares of HOLX stock opened at $81.59 on Wednesday. The stock has a market capitalization of $20.12 billion, a price-to-earnings ratio of 15.94, a P/E/G ratio of 1.50 and a beta of 1.00. The company has a current ratio of 4.12, a quick ratio of 3.45 and a debt-to-equity ratio of 0.58. Hologic has a twelve month low of $59.78 and a twelve month high of $81.97. The stock has a fifty day simple moving average of $76.28 and a two-hundred day simple moving average of $71.32.

Analyst Ratings Changes

Several research analysts have issued reports on HOLX shares. Royal Bank of Canada initiated coverage on shares of Hologic in a report on Tuesday, December 6th. They set a “sector perform” rating and a $75.00 target price on the stock. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Friday, December 16th. Wells Fargo & Company upped their target price on Hologic from $75.00 to $80.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 10th. Evercore ISI lifted their price target on Hologic from $65.00 to $70.00 and gave the company an “in-line” rating in a report on Tuesday, November 1st. Finally, Morgan Stanley boosted their price target on Hologic from $68.00 to $74.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 1st. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $79.83.

Insider Activity

In related news, General Counsel John M. Griffin sold 26,902 shares of Hologic stock in a transaction that occurred on Monday, November 14th. The shares were sold at an average price of $76.12, for a total value of $2,047,780.24. Following the completion of the sale, the general counsel now directly owns 168,944 shares in the company, valued at approximately $12,860,017.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, General Counsel John M. Griffin sold 26,902 shares of the company’s stock in a transaction on Monday, November 14th. The stock was sold at an average price of $76.12, for a total value of $2,047,780.24. Following the transaction, the general counsel now directly owns 168,944 shares of the company’s stock, valued at approximately $12,860,017.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Karleen Marie Oberton sold 14,545 shares of Hologic stock in a transaction dated Tuesday, November 1st. The stock was sold at an average price of $72.50, for a total value of $1,054,512.50. Following the sale, the chief financial officer now directly owns 126,811 shares of the company’s stock, valued at approximately $9,193,797.50. The disclosure for this sale can be found here. Corporate insiders own 1.66% of the company’s stock.

Hedge Funds Weigh In On Hologic

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Hologic by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 27,882,301 shares of the medical equipment provider’s stock valued at $2,141,919,000 after acquiring an additional 381,608 shares during the last quarter. State Street Corp boosted its holdings in Hologic by 0.8% in the first quarter. State Street Corp now owns 11,426,634 shares of the medical equipment provider’s stock valued at $877,794,000 after purchasing an additional 94,561 shares during the last quarter. Macquarie Group Ltd. raised its stake in shares of Hologic by 227.2% during the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock valued at $435,485,000 after buying an additional 4,363,687 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Hologic by 4.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,305,399 shares of the medical equipment provider’s stock valued at $177,098,000 after buying an additional 106,315 shares during the period. Finally, Invesco Ltd. boosted its stake in shares of Hologic by 7.1% in the first quarter. Invesco Ltd. now owns 2,004,276 shares of the medical equipment provider’s stock worth $153,967,000 after buying an additional 133,284 shares during the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

About Hologic

(Get Rating)

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.

Featured Stories

Earnings History for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.